Phase 2 Trial of NP-120 for IPF Reaches 25% of Enrollment Target
A Phase 2 study of NP-120 (ifenprodil) for chronic cough associated with idiopathic pulmonary fibrosis (IPF) has reached 25% of its enrollment target, Algernon Pharmaceuticals, the therapy’s developer, has announced. “I am very pleased to report that we have reached 25% enrollment in the study,” Christopher J. Moreau, CEO…